Editors' ChoiceCancer

B cell lymphoma R-CHOPped by metabolic inhibitors

See allHide authors and affiliations

Science Translational Medicine  27 Mar 2019:
Vol. 11, Issue 485, eaax3456
DOI: 10.1126/scitranslmed.aax3456


Some patients with diffuse large B cell lymphoma are resistant to conventional combination therapy but respond to metabolic inhibitors.

View Full Text

Stay Connected to Science Translational Medicine